secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001213900-23-013281
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell reports net loss of $2.5M for 2022; second contamination event slows Q1 2023 production
--------------------------------------------------------------------------------

- Net loss of $2.5M ($0.32 per share) vs loss of $78k in 2021; gross margin fell to 41% from 45%.
- EBITDA dropped to $350k from $2.7M; cash decreased to $5.8M from $10.2M.
- Second contamination event detected in Q1 2023; production slowdown and backlog more than doubled since year-end.
- Deferred planned capacity expansion to over $40M/year due to lost gross margin in Q1 2023.
- Aiming to re-submit CMC Technical Section for Re-Tain to FDA in Q1 2023, subject to external lab results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390023013281/0001213900-23-013281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390023013281/ea174041-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-013281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer